Skip to content
Sharism- Lifestyle
Author:
Actuate Therapeutics
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
November 4, 2026
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
November 2, 2026
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
October 27, 2026
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
September 9, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
June 9, 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 11, 2026